Client: BioRender
Year: 2021
Media: BioRender, Adobe Illustrator, Adobe Photoshop, Autodesk Maya
An infographic created using and for BioRender, a tool that aids researchers, students, and scientists in creating professional figures using pre-made icons and templates. It describes emerging methods for tackling cancer, such as mutation-specific drugs, vaccines, and targeting the microenvironment around the tumour itself, using a KRAS-mutant tumour as an example. I created the tumour icon as a new BioRender asset for this infographic, and the infographic was created in collaboration with Michie Wu.
References
Academic Sources
The ASCO Post Staff. (2021). FDA approves sotorasib for KRAS G12C-mutated NSCLC. The ASCO Post. Retrieved on August 21, 2021, from https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., Lanman, B. A., Werner, J., Rapaport, A. S., San Miguel, T., Ortiz, R., Osgood, T., Sun, J. R., Zhu, X., McCarter, J. D., Volak, L. P., … Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217–223. https://doi.org/10.1038/s41586-019-1694-1
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020). The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.00940
Whiteside T. L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27(45), 5904–5912. https://doi.org/10.1038/onc.2008.271
Zhang, Y., Ma, J. A., Zhang, H. X., Jiang, Y. N., & Luo, W. H. (2020). Cancer vaccines: Targeting KRAS-driven cancers. Expert review of vaccines, 19(2), 163–173. https://doi.org/10.1080/14760584.2020.1733420